2015 Volume 3 Issue 1 Pages 58-61
【Objectives】To investigate the association of genetic polymorphisms and cyclosporine (CyA) dosage with CyA blood levels in renal transplant recipients.【Methods】Seventy-six patients who received CyA in our institution from June 2004 to June 2010 were genotyped for single nucleotide polymorphisms (SNPs) in CYP3A4, CYP3A5, and MDR1 exon21, 26. Additionally, the dose and trough blood levels were compared among the patients according to allelic CYP3A4, CYP3A5, and MDR1 status.【Results】The dose administered during the perioperative period was 7.49±0.76 mg/kg, 4.31l±1.30mg/kg 3 months post-transplantation, 4.05±1.24mg/kg 6 months after transplantation.Three months after transplantation, no significant difference was observed in the trough blood level in patients with a CYP3A5 polymorphism；however, the dose in patients with wild type CYP3A5 was less than that in patients with heterozygous and mutant type CYP3A5. In contrast, no association was detected between the dose and genetic polymorphisms in MDR1 exon21, 26.【Conclusions】Our evaluation of renal transplant recipients suggest that the CYP3A5 may affect CyA pharmacokinetics, but the exact effect remains unclear. In CyA pharmacokinetics, it may be necessary to search and validate the other polymorphisms which are neither CYP3A nor MDR1.
